Crowdonomics
All companies

Promicell, Inc.

Operating

Biotech · Miami, FL

Estimated pre-money ⓘ
$92.1M
As of May 2025 · from Reg A Offering (2025) · our estimate: offering price × shares outstanding, not a stated valuation
Total raised
$0
Across 1 round since 2025
Latest share price
$5.00
Reg A Offering (2025) offering price

Financials

FY2024 · from SEC filings · hover any figure for its source
$0
−$3.6M
2024
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2024 audited
Income statement
Revenue
$0
Cost of goods sold
$0
Net income
-$3,621,456
Balance sheet
Cash
$3,646,623
Accounts receivable
$0
Total assets
$5,508,810
Long-term debt
$0
Total liabilities
$217,926
Other
Headcount
0

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$92.1M
est. pre-money
Reg A+ · Equity · May 2025

Dotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.

Cap table

Share counts as of Jul 17, 2025
preferred stock · 17.8%Common Stock · 41.1%Class A Common · 40.9%Class B · 0.22%
ClassOutstandingVotes / shareShare of totalVotesLast price
preferred stockpreferred(as of Dec 31, 2024)8,000,000—17.8%5.52%—
Common Stock(as of Dec 31, 2024)18,516,100—41.1%12.8%—
Class A Common18,416,100140.9%12.7%—
Class B100,0001,0000.22%69.0%—
Total45,032,200100%100%

Shares outstanding over timein today's share terms

27M13M0
Dec 2023May 2025
Class A CommonClass BCommon Stockpreferred stock

Changes in named holdersshares in today's terms · % of all shares at the time

Principal holders% as the filing states it, Jul 17, 2025

  • Miltiadis Sougioultzoglou100,000 Class B Common100.0%of Class B
  • Prime Cap Ventures Inc.4,450,000 Series A Preferred Stock55.6%of Series A Preferred
  • Miltiadis Sougioultzoglou4,688,775 Class A Common25.5%of Class A
  • Prime Cap Ventures Inc.2,000,000 Class A Common10.9%of Class A
  • Anthony Argyropoulos851,434 Class A Common4.62%of Class A
  • John Glasspool388,484 Class A Common2.11%of Class A

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Reg A+ · Equity · May 2025Withdrawnvia DALMORE GROUP LLC
Raised $0 / $75MEst. pre-money $92.1M

Team

9 people
Miltiadis Sougioultzoglou, MD
Chief Executive Officer
Anthony Argyropoulos
Chief Financial Officer
Anthony Daniyan, MD
Chief Scientific Officer
John K. Lee, MD, PhD
Chief Medical Officer
Matthew Jacobson
Chief Legal Officer
Eric Holland, MD
Independent Director
Gregory Raskin, MD
Independent Director
Nikhil Mehta, PhD
Independent Director
R. John Glasspool
Independent Director

Names and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.

SEC filings

  • Form 1-A-WMay 5, 20260001213900-26-052100
    EDGAR
  • Form 1-A/AJul 17, 20250001213900-25-065167
    EDGAR
  • Form 1-A/AJul 2, 20250001213900-25-061106
    EDGAR
  • Form 1-AMay 29, 20250001213900-25-048870
    EDGAR
Source: SEC EDGARCIK 0002055281DEShare price $5.00Last synced Aug 16, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.